Suppr超能文献

淀粉样变性、结节病和血色素沉着症患者经皮冠状动脉介入治疗的临床结果

Clinical Outcomes of Percutaneous Coronary Intervention in Amyloidosis, Sarcoidosis, and Hemochromatosis.

作者信息

Hussain Bilal, Malik Hamza, Mamas Mamas A, Desai Rupak, Aggarwal Vikas, Kumar Gautam, Alraies M Chadi, Kalra Ankur, Paul Timir K

机构信息

Department of Internal Medicine, The Brooklyn Hospital Center, Brooklyn, New York.

Department of Internal Medicine, Central Michigan University, Saginaw, Michigan.

出版信息

J Soc Cardiovasc Angiogr Interv. 2023 Dec 30;3(4):101267. doi: 10.1016/j.jscai.2023.101267. eCollection 2024 Apr.

Abstract

BACKGROUND

Infiltrative diseases (IDs), including amyloidosis, sarcoidosis, and hemochromatosis, are characterized by abnormal cellular infiltration in multiple organs, including the heart. The prognosis of percutaneous coronary intervention (PCI) patients with underlying IDs has not been well-studied. We evaluated the prevalence of IDs in patients undergoing PCI and their association with post-PCI outcomes.

METHODS

The National Inpatient Sample (NIS) 2016-2020 database was used to identify PCI patients with ICD-10 codes for a retrospective analysis. PCI patients were then divided into those with and without underlying IDs, which included amyloidosis, sarcoidosis, and hemochromatosis. Multivariable logistic regression was performed for composite post-PCI outcomes analyses.

RESULTS

Among 2,360,860 patients admitted to undergo PCI, 7855 patients had underlying IDs. The highest prevalence was observed for sarcoidosis (0.2%) followed by hemochromatosis (0.07%) and amyloidosis (0.04%). Underlying amyloidosis was associated with worse composite post-PCI outcomes (odds ratio [OR], 1.6; 95% CI, 1.1-2.44; = .02), including higher in-hospital mortality (OR, 1.9; 95% CI, 1.1-3.4; = .04), higher risk of intra/post-PCI stroke (OR, 4.0; 95% CI, 1.1-16.0; = .04), but not major bleeding (OR, 2.2; 95% CI, 0.97-5.03; = .058). In contrast, underlying sarcoidosis (OR, 1.1; 95% CI, 0.87-1.41; = .4), and hemochromatosis (OR, 1.18; 95% CI, 0.77-1.8; = .44) were not associated with composite post-PCI outcomes. Amyloidosis patients undergoing PCI also had higher hospitalization charges ($212,123 vs $141,137; = .03) and longer length of stay (8.2 vs 3.9 days; < .001).

CONCLUSIONS

Underlying amyloidosis was associated with worse post-PCI outcomes including higher in-hospital mortality, intra/post-PCI stroke, and socioeconomic burden. A multidisciplinary approach and future studies are needed to investigate the screening and treatment strategies in these patients.

摘要

背景

浸润性疾病(IDs),包括淀粉样变性、结节病和血色素沉着症,其特征是包括心脏在内的多个器官出现异常细胞浸润。患有潜在浸润性疾病的经皮冠状动脉介入治疗(PCI)患者的预后尚未得到充分研究。我们评估了接受PCI治疗的患者中浸润性疾病的患病率及其与PCI术后结局的关联。

方法

使用2016 - 2020年国家住院患者样本(NIS)数据库,通过ICD - 10编码识别PCI患者,进行回顾性分析。然后将PCI患者分为有或无潜在浸润性疾病(包括淀粉样变性、结节病和血色素沉着症)两组。对PCI术后综合结局进行多变量逻辑回归分析。

结果

在2360860例接受PCI治疗的患者中,7855例患有潜在浸润性疾病。结节病的患病率最高(0.2%),其次是血色素沉着症(0.07%)和淀粉样变性(0.04%)。潜在淀粉样变性与PCI术后更差的综合结局相关(优势比[OR],1.6;95%置信区间,1.1 - 2.44;P = 0.02),包括更高的住院死亡率(OR,1.9;95%置信区间,1.1 - 3.4;P = 0.04)、PCI术中/术后更高的中风风险(OR,4.0;95%置信区间,1.1 - 16.0;P = 0.04),但与大出血无关(OR,2.2;95%置信区间,0.97 - 5.03;P = 0.058)。相比之下,潜在结节病(OR,1.1;95%置信区间,0.87 - 1.41;P = 0.4)和血色素沉着症(OR,1.18;95%置信区间,0.77 - 1.8;P = 0.44)与PCI术后综合结局无关。接受PCI治疗的淀粉样变性患者住院费用也更高(212123美元对141137美元;P = 0.03),住院时间更长(8.2天对3.9天;P < 0.001)。

结论

潜在淀粉样变性与PCI术后更差的结局相关,包括更高的住院死亡率、PCI术中/术后中风以及社会经济负担。需要采取多学科方法并开展进一步研究来探讨这些患者的筛查和治疗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9157/11308414/a07c4f30726f/ga1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验